Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ADAM17 cytoplasmic domain modulates Thioredoxin-1 conformation and activity.
E Costa RAP, Granato DC, Trino LD, Yokoo S, Carnielli CM, Kawahara R, Domingues RR, Pauletti BA, Neves LX, Santana AG, Paulo JA, Aragão AZB, Heleno Batista FA, Migliorini Figueira AC, Laurindo FRM, Fernandes D, Hansen HP, Squina F, Gygi SP, Paes Leme AF. E Costa RAP, et al. Among authors: hansen hp. Redox Biol. 2020 Oct;37:101735. doi: 10.1016/j.redox.2020.101735. Epub 2020 Sep 24. Redox Biol. 2020. PMID: 33011677 Free PMC article.
Thioredoxin-1 Negatively Modulates ADAM17 Activity Through Direct Binding and Indirect Reductive Activity.
Granato DC, E Costa RAP, Kawahara R, Yokoo S, Aragão AZ, Domingues RR, Pauletti BA, Honorato RV, Fattori J, Figueira ACM, Oliveira PSL, Consonni SR, Fernandes D, Laurindo F, Hansen HP, Paes Leme AF. Granato DC, et al. Among authors: hansen hp. Antioxid Redox Signal. 2018 Sep 10;29(8):717-734. doi: 10.1089/ars.2017.7297. Epub 2018 Feb 27. Antioxid Redox Signal. 2018. PMID: 29334756
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin.
Lobastova L, Lettau M, Babatz F, de Oliveira TD, Nguyen PH, Pauletti BA, Schauss AC, Dürkop H, Janssen O, Paes Leme AF, Hallek M, Hansen HP. Lobastova L, et al. Among authors: hansen hp. Front Cell Dev Biol. 2021 Jul 30;9:698503. doi: 10.3389/fcell.2021.698503. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34395429 Free PMC article.
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
Hansen HP, Trad A, Dams M, Zigrino P, Moss M, Tator M, Schön G, Grenzi PC, Bachurski D, Aquino B, Dürkop H, Reiners KS, von Bergwelt-Baildon M, Hallek M, Grötzinger J, Engert A, Paes Leme AF, Pogge von Strandmann E. Hansen HP, et al. Oncotarget. 2016 May 24;7(21):30523-35. doi: 10.18632/oncotarget.8864. Oncotarget. 2016. PMID: 27105521 Free PMC article.
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M, Krönke M, Hallek M, Pogge von Strandmann E. Reiners KS, et al. Among authors: hansen hp. Blood. 2013 May 2;121(18):3658-65. doi: 10.1182/blood-2013-01-476606. Epub 2013 Mar 18. Blood. 2013. PMID: 23509156 Free PMC article.
ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.
Trad A, Hansen HP, Shomali M, Peipp M, Klausz K, Hedemann N, Yamamoto K, Mauermann A, Desel C, Lorenzen I, Lemke H, Rose-John S, Grötzinger J. Trad A, et al. Among authors: hansen hp. Cancer Immunol Immunother. 2013 Mar;62(3):411-21. doi: 10.1007/s00262-012-1346-x. Epub 2012 Sep 1. Cancer Immunol Immunother. 2013. PMID: 22940887 Free PMC article.
147 results